➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Colorcon
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School

Last Updated: May 17, 2021

DrugPatentWatch Database Preview

TWINJECT 0.15 Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Twinject 0.15 patents expire, and when can generic versions of Twinject 0.15 launch?

Twinject 0.15 is a drug marketed by Impax and is included in one NDA. There are two patents protecting this drug.

This drug has forty-three patent family members in fifteen countries.

The generic ingredient in TWINJECT 0.15 is epinephrine. There are twenty-one drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Twinject 0.15

A generic version of TWINJECT 0.15 was approved as epinephrine by BELCHER on July 29th, 2014.

  Get Started Free

Drug patent expirations by year for TWINJECT 0.15
Recent Clinical Trials for TWINJECT 0.15

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Arthroplasty Foundation, Inc.Phase 4
University of LouisvillePhase 4

See all TWINJECT 0.15 clinical trials

US Patents and Regulatory Information for TWINJECT 0.15

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impax TWINJECT 0.15 epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 020800-002 May 28, 2004 DISCN No No   Get Started Free   Get Started Free Y   Get Started Free
Impax TWINJECT 0.15 epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 020800-002 May 28, 2004 DISCN No No   Get Started Free   Get Started Free Y   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Moodys
Baxter
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.